Abstract 1953P
Background
The diversity of clinical and pathological characteristics of soft tissue sarcoma (STS) presents a challenge for the prediction of prognosis. Recently, pretreatment inflammatory markers have gained interest as predictive factors for survival in cancer patients. The aim of this study is to evaluate inflammatory markers as a predictive biomarker for early recurrence in STS.
Methods
118 patients with primary, localized soft tissue sarcoma were retrospectively reviewed for early recurrence. Early recurrence was defined as a disease relapse (local or distant) within the first year after diagnosis. Pretreatment inflammatory markers including leukocytes, interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and other variables including tumor grade, tumor Departmenth, location, size, and the presence of tumor necrosis on imaging were analyzed for their association with early recurrence. Survival data was analyzed using Log-rank test and Cox regression to identify prognostic factors for early recurrence.
Results
Pretreatment IL-6 elevation was associated with higher tumor grade, increased size, and necrosis on imaging. Elevated CRP was associated with higher tumor grade, NLR and PLR with tumor Departmenth, and PLR with tumor location. Early recurrences were found in 23 of 118 patients (19.5%): 7 local, 15 distant recurrences and 1 with both manifestations. Univariate analysis revealed that tumor grade (low vs high, p = 0.008), tumor Departmenth (superficial vs deep, p = 0.005), and IL-6 level (< 7 vs ≥ 7 ng/L, p = 0.012) were significantly associated with early recurrence; other inflammatory markers including leukocytes, CRP, NLR and PLR were not. Multivariate analysis did not reveal independent risk factors associated with the development of early recurrences in STS, although the number of cases were low.
Conclusions
Early recurrences in STS are not only associated with higher grade and deeper tumors, but also with increased plasma levels of IL-6.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W.T.A. Van Der Graaf: Financial Interests, Institutional, Advisory Board: PTC Therapeutics, Agenus, SpringworksTx; Financial Interests, Institutional, Local PI, Clinical study: Springworks, Boehringer Ingelheim; Financial Interests, Institutional, Research Grant, IIS: Lilly; Financial Interests, Institutional, Local PI, Clinical Study: AYALA; Non-Financial Interests, Member of Board of Directors, President: EORTC; Non-Financial Interests, Member of Board of Directors: European Cancer Organisation; Non-Financial Interests, Member of Board of Directors, Chair: Dutch Sarcoma Group, Dutch AYA 'Young and Cancer' Care Network. D. Van Den Broek: Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Expert Testimony: Roche; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Funding: ZonMW, Delfi Diagnostics. N. Steeghs: Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim, Ellipses Pharma, Luszana; Financial Interests, Personal, Advisory Board: GSK, Incyte; Financial Interests, Institutional, Local PI: AbbVie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, BMS, Cantargia, CellCentric, Cogent Biosciences, Crescendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GSK, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer, Deciphera, GSK, Lixte, Merck, Novartis, Pfizer, Roche. W. Van Houdt: Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Advisory Board: Belpharma, Sanofi, MSD; Financial Interests, Personal, Other, travel grant: Novartis; Financial Interests, Institutional, Local PI: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15